Cardiovascular and Renal Drugs Advisory Committee; Amendment of Notice

Özet

The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Cardiovascular and Renal Drugs Advisory Committee. This meeting was originally announced in the Federal Register of August 1, 2006 (71 FR 43487). The amendment is being made to reflect changes in the Agenda portion of the document. The word "TRASYOL" should read "TRASYLOL". In the same paragraph, the word "apportioning" should read "aprotinin". There are no other changes.